On Air Now

Listen

Listen Live Now » 92.9 FM Lansing, Michigan

Weather

Current Conditions(Holt,MI 48842)

More Weather »
44° Feels Like: 38°
Wind: SSE 13 mph Past 24 hrs - Precip: 0”
Current Radar for Zip

Tonight

Partly Cloudy 32°

Tomorrow

Partly Cloudy 62°

Thurs Night

Showers Late 42°

Alerts

GlaxoSmithKline diabetes drug faces U.S. approval delay

The GlaxoSmithKline building is pictured in Hounslow, west London June 18, 2013. REUTERS/Luke MacGregor
The GlaxoSmithKline building is pictured in Hounslow, west London June 18, 2013. REUTERS/Luke MacGregor

LONDON (Reuters) - U.S. regulators have pushed back an approval decision on GlaxoSmithKline's experimental diabetes drug albiglutide by three months until April 15, 2014, Britain's biggest drugmaker said on Friday.

A separate filing for the drug in Europe is progressing on schedule.

The once-weekly treatment for type 2 diabetes belongs to the same class of injectable GLP-1 drugs as Victoza, from Novo Nordisk, and Byetta and Bydureon, from Bristol-Myers Squibb and AstraZeneca.

Based on reported clinical trial results, industry analysts have questioned how well albiglutide will fare in a crowded market - especially with a promising new rival in the pipeline in the form of Eli Lilly's dulaglutide.

(Reporting by Ben Hirschler; Editing by Keith Weir)

Comments